With Five Guidances, FDA Overhauls Its Advisory Committee Policies
This article was originally published in The Gray Sheet
Executive Summary
FDA should hold voluntary advisory committee meetings only for matters that are of significant public interest or controversy, or that demand unique expertise, the agency's Office of Policy, Planning and Preparedness says in a 1draft guidance released Aug. 5